Expanding reimbursement of immediate treatment using direct acting antivirals to reduce hepatitis C incidence among HIV positive men who have sex with men in Bangkok, Thailand: A cost effectiveness modelling study

Shreoshee Mukherjee a,*, Donn Colby b, c, d, Reshmie Ramautarsing d, Stephanie Popping a, e, Somchai Sriplienchan d, Tanat Chinbunchorn d, Nittaya Phanuphak d, David van de Vijver a, **

a Erasmus MC, Department of Viroscience, Rotterdam, the Netherlands
b United States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA
c The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
d Institute of HIV Research and Innovation, Bangkok, Thailand
e Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, the Netherlands

ARTICLE INFO

Keywords:
MSM
Cost effectiveness
Hepatitis C
HIV
Direct acting antivirals
Micro elimination
Thailand
Asia

ABSTRACT

Background: Increasing number of hepatitis C virus (HCV) infections among HIV positive men who have sex with men (MSM) as in an acute HIV infection cohort study in Bangkok, reached an incidence of 45/1000 person-years in 2018. Direct-acting antivirals (DAAs), that cure HCV infection and thereby can prevent transmission, are expensive, their reimbursement being presently delayed to the chronic stages of liver fibrosis. The aim of this study was to determine the cost-effectiveness of immediate DAA treatment to reduce HCV transmission among HIV positive MSM in Bangkok.

Methods: A deterministic transmission model was calibrated to the HCV epidemic among HIV positive MSM in Bangkok. We compared the current practice of starting DAAs at METAVIR stage F2 rather than at stage F1, or immediately after diagnosis, at stage F0. Cost-effectiveness was examined from a payer’s perspective, using a 3% annual discounting rate.

Results: Compared to the incidence in 2018, delaying DAA treatment to METAVIR stage F2 or F1, increases HCV incidence in 2030 to 63/1000 person-years and 56/1000 person-years, respectively. Conversely, immediate DAA treatment reduces the incidence to 26/1000 person-years. Compared to initiating treatment at stage F2, immediate treatment is cost saving within seven years and saves $17 million over 40 years. One-way sensitivity analysis showed that lower cost savings were achieved at a higher price of DAA treatment and at less frequent HCV screening.

Conclusion: Immediate DAA treatment is cost saving and increases health benefits by reducing HCV incidence among HIV-infected MSM.

Introduction

Hepatitis C virus (HCV) is a major global health issue, affecting an estimated 71 million individuals globally.1 The introduction of direct-acting antiviral (DAA) drugs in 2014 has been a breakthrough in the treatment of HCV with more than 95% cure rates.2 DAAs have also improved prevention, as cured individuals cannot transmit the virus to others.3,4 Recognizing this breakthrough, the World Health Organization declared in 2017 the ambitious goal of eliminating HCV transmission by 2030.5

In Bangkok, an emerging HCV epidemic has been observed among HIV positive men who have sex with men (MSM). As part of the SEARCH 010/RV254 acute HIV cohort study based in Bangkok, HIV positive MSM were followed up routinely and screened for HCV infection during
their HIV clinical care. Although no new HCV infections were observed before 2014, the incidence increased to 45 per 1000 person years by 2018. According to the latest Thailand Practise Guideline to Elimination of Hepatitis C published on May 2, 2020, DAAs are recommended irrespective of the stage of fibrosis. However, as per the National Health Security Office reimbursement criteria, DAAs are restricted to the more advanced stages of fibrosis by only reimbursing DAAs for METAVIR stage F2 and higher of liver fibrosis. Additionally, as per our guidelines, HCV screening is conducted annually among HIV positive people who inject drugs (PWID). Given the increase in incidence among HIV positive MSM, baseline and annual testing for HCV could allow for improved diagnosis. Subsequently, reimbursement of DAA treatment unrestricted by the stage of liver fibrosis could enhance DAA uptake, resulting in health benefits and reduced HCV transmission. In this study, we aim to assess whether the costs of expanding DAA reimbursement in Thailand for genotype-1a in HIV/HCV coinfected MSM is affordable for the Thai government using epidemiological, cost-effectiveness and budget impact of DAA treatment analysis.

Methods

Deterministic transmission model

A previously published Dutch deterministic HCV transmission model was calibrated to represent the Thai HCV epidemic among HIV-infected MSM from 2015 to 2018. The emerging HCV epidemic has been well described by the SEARCH 010/RV254 research team in Bangkok that collects data on all relevant parameters such as the number of new HCV infections to analyse epidemiological trends, HCV phylogenetic distribution, route of transmission, cost of treatment and economic impact.

Model assumptions and calibration

The Dutch model was adapted to represent the Thai HCV epidemic amongst HIV positive MSM (Table 1 and supplement). We calibrated our model to the historic HCV epidemic using the estimated Bangkok MSM population size (120,000 to 250,000) with a 5-year growth rate (2.31%), proportion of MSM infected with HIV (19.5%), proportion of HIV positive MSM diagnosed with HCV (8.7%), rate of new HCV infections (32.3 per 1000 person years in 2017, 44.8 per 1000 person years in 2018), and rate of HCV reinfection of 14.1% [5%–19%] after treatment or spontaneous clearance. Using Monte Carlo filtering technique, we accepted 128 simulations of 100,000 as per the calibration range that represented the Thai HCV epidemic among the HIV positive MSM. We included variables such as duration of treatment, the population of HCV/HIV co-infected MSM in the year 2013, when the model is seeded.

The model stratifies into those individuals who were not infected, those infected, and those who have been cured but susceptible to reinfection. Further, infection with HCV was stratified by patients undergoing spontaneous clearance (15–20%) or moving into three progressive stages of fibrosis (METAVIR stage F0, F1, F2, F3), two stages of cirrhosis (F4; compensated cirrhosis and decompensated cirrhosis) which in turn could lead to development of hepatocellular carcinoma. At each stage of disease progression, the model was compartmentalized into individuals undergoing treatment with DAAs and those who did not achieve a sustained virological response after treatment. The schematic representation of the model along with the equations can be found in Fig. S1 of the supplement.

In the baseline scenario, individuals start treatment with DAAs at METAVIR stage F2, since they are reimbursed at this stage as per the Thai hepatitis C management guidelines. The base case is then compared to two scenarios in which a) DAAs were prescribed at METAVIR stage F1 and, b) immediately after diagnosis. Duration of treatment was 12 or 24 weeks, for treatment in stage F0 through F3 or people who had cirrhosis, respectively. The probability of achieving SVR varies between 95 and 100% in stage F0 through F3 of fibrosis, and 80–90% for cirrhosis. We took quality-adjusted life-year (QALY) estimates depending upon the model compartment or the stage of disease progression (Table 1). All results predicting prevalence, incidence, number of infections averted, cost incurred, health utilities with respect to quality-adjusted life-years (QALYs) gained, are reported as median and interquartile range (IQR) of the accepted simulations.

Table 1

| Modelling parameters. | Value [range] | Source |
|-----------------------|-------------|--------|
| Entry rate of HIV-infected MSM | Varied over annual sexual risk activity e.g., number of new sexual partners | Calibrated |
| Proportion of MSM in risk groups | P1: highest risk group [0.01, 0.15] | Calibrated |
| Year of HCV epidemic seeding | 2013 | Calibrated |
| Life expectancy of Thai men at birth (total years) | 73 years | |
| Mortality | 1/45 | 27 |
| Proportion of HIV-positive who spontaneously clear acute HCV infection | 15–20% | 13,20,29 |
| Duration until spontaneous clearance | 40–170 days | 29 |
| SVR with DAA | Fibrosis | 98.5% [95–100%] |
| Compensated cirrhosis | [80–95%] |
| Decompensated cirrhosis | [70–80%] |
| Duration of treatment | Fibrosis | 12 weeks |
| Cirrhosis | 24 weeks |
| Quality Adjusted Life Years (QALYs) | QALYs when only HIV positive | 0.94 |
| QALYs in compensated cirrhosis | 0.38 + 0.5*0.29 |
| QALYs in compensated cirrhosis | 0.38 |
| QALYs in hepatocellular carcinoma | 0.45 |

Parameters used for model fitting (point estimate, range)

| HCV incidence among diagnosed HIV-positive MSM | 2017 | 32.3 per 1000 [22–43] |
| 2018 | 44.8 per 1000 [35–55] |
| HCV prevalence among diagnosed HIV-positive MSM | 8.7% [7.5–10%] |
| HCV reinfection rate after treatment or spontaneous clearance | 14.1% [9–19%] |
| Number of MSM in 2015 | 185,000 [120000–250000] |
| HIV Prevalence among MSM | 19.5% [23000–49000] |
Cost-effectiveness methods to recognize optimal treatment scenario

The cost-effectiveness analysis used a payer’s perspective over a lifetime, a 40-year time horizon, at 3% annual discounting. Costs were valued in 2020 US dollars (USD) (1 Thai Baht = 0.032 USD) and health outcomes were valued in QALY. Costs of drugs and diagnostic tests were used as per the Thai Hepatitis C Management Guidelines 2018 which delineates the associated protocols during screening, diagnosis, and treatment. The associated costs at each stage or compartment of the HCV transmission mathematical model correspond to the diagnostic tests and drugs used in that compartment, extracted from centralized regional public hospitals by the SEARCH 010/RV254 research team. The costs of the DAA drugs were taken for a combination of sofosbuvir/ledipasvir used to treat HCV-infected patients with the genotype 1.

The median and interquartile range of the costs and QALYs were tabulated for each accepted simulation at every stage of fibrosis. Thereafter, increment in costs and QALYs were calculated. The incremental cost-effectiveness ratio (ICER) for the intervention scenarios was then evaluated to make the cost-effectiveness table. The intervention with the highest ICER was selected as the most cost-effective intervention while other scenarios were deemed to be dominated. We also examined the short-term budget impact over 10 years on undiscounted costs cumulated for immediate and early-stage treatment intervention.

One-way sensitivity analysis

We performed a one-way sensitivity analysis to assess the impact of uncertainty in the costs of drugs and diagnostic parameters on the incremental cost-effectiveness ratio over 40 years for immediate DAA treatment. We examined how sensitive the modelled cost-effectiveness was to changes in the input cost variables. The cost of 12-week regimen of DAA-based drug combination sofosbuvir/ledipasvir in Thailand is 13,860 THB or 445.8 USD, which was varied to upper and lower limits over a range of 50%. The upper limit was considered as 20,790 THB or 668 USD while the lower limit was considered as 6930 THB or 222.9 USD. We varied the costs of the rest of the diagnostic tests as per the range of the cost as charged in public hospitals. We also varied the frequency of HCV RNA tests conducted from 6 months to 1 year and 3 years.

We performed a multivariate sensitivity analysis using recursive partitioning to determine the most influential independent parameters on the cost-effectiveness of the DAA-based treatment of HCV. The impact of parameters like the incidence rate, prevalence, reinfection rate was observed on the cost-effectiveness of immediate treatment as compared to the base case scenario.

Results

Our model projects that continuing delaying DAA to METAVIR stage F2 of liver fibrosis, increases the incidence rate of HCV infection from 45 per 1000 person-years in 2018 to 63 per 1000 person-years of follow-up in 2030 among HIV-infected MSM. If DAA are started in stage F1, then the increase in incidence is relatively lower, going up to 56 per 1000 person years of follow-up in 2030. Immediate treatment with DAA upon diagnosis has a profound preventative impact on HCV infection as indicated by a reduction in incidence rate to 26 per 1000 person-years of follow-up in 2030 (Fig. 1).

Continuing the current practice of delaying treatment to fibrosis stage F2 will have a profound impact on the HCV prevalence among HIV positive MSM in Thailand, which will increase from 8.7% in 2018 to 13.7% in 2030. Starting treatment earlier at stage F1 will result in a prevalence of 8.3% in 2030. However, the prevalence is predicted to dramatically decrease by over 80% if the treatment is initiated immediately upon diagnosis, reducing to 1.5% in 2030 (Fig. 2).

The strong impact of immediate treatment is also reflected in the number of HCV infections averted until 2030 among HIV-infected MSM. With the treatment being initiated at F1 stage rather than the delayed F2 stage of fibrosis, only 474 new infections are predicted to be averted through 2030, whereas 5939 new infections are averted if the DAA-based treatment is initiated immediately upon diagnosis rather than F2 stage of liver fibrosis (Fig. 3).

The discounted cumulative costs of DAA treatment of HIV-infected MSM will be 46 million USD [IQR: 35.3–51.6] in Thailand if DAA are introduced at stage F2. Compared to the base case scenario, advancing the treatment to F1 stage will lead to economic gains, saving 5 million USD [IQR: 4.2–5.8]. Importantly, early treatment at F0 stage of fibrosis would save substantial costs worth 17 million USD [IQR: 14.3–18.8] over the lifetime period of 40 years. Similarly, the quality-adjusted life years (QALYs) are observed to increase with an earlier treatment stage from the delayed F2 stage (900,000) to the chronic F1 stage (903,000) and finally to the early acute F0 stage (906,000) of liver fibrosis as the number of new infections averted improve with expansion of treatment. Thus, the incremental cost-effectiveness ratio is inferred for stage F0 to be the most cost-effective stage of intervention while the chronic F1 stage and delayed chronic F2 stages of liver fibrosis are dominated, as shown in Table 2.

Fig. 2 shows that expanding the DAA-based treatment to the early acute F0 stage of fibrosis would be initially expensive because the HIV-infected MSM population under treatment coverage will go up. However, within seven years, we observe that the costs saved from averti
new infections by expanding treatment from F2 stage to F0 stage exceeded the costs incurred in expanding the treatment to early acute stage F0 of liver fibrosis. Therefore, within seven years, the investment on expanding the DAA-based treatment to the early stages of fibrosis breaks even and is recovered from the costs forgone by averting new infections.

The one-way sensitivity analysis in Fig. 3 shows the impact of varying the costs of drugs and diagnostic tests on the cost-effectiveness ratio. The model predicted that the cost of DAAs has the strongest impact on cost savings as compared to other cost inputs when treatment is started immediately in F0 as compared to the base case F2. Testing for HCV at a 6 months' interval is more cost saving than testing once a year or once in 3 years. As can be seen in Fig. 3, changing the price of ultrasound and fibrosis scan costs have an impact on cost savings, whereas HCV genotyping has no impact on cost savings. Further, we conducted multivariate sensitivity analysis which showed that the magnitude of the incidence rate in the year 2030 had a dominant impact on cost-effectiveness. This could be ascribed to the fact that the cost of elimination can have a U shape curve. Initial costs of investments into expanding treatment are high, which progressively are reduced, only to become high again. Finding the last infected individuals in the population is expensive. Other variables that were also significantly impacting the cost-effectiveness were percentages of reinfections, number of people diagnosed with acute HCV infection, proportion of people transitioning from delayed stage 4 of fibrosis to compensated cirrhosis, and proportion of people in the highest sexual risk activity class [Suppl.

### Table 2

Cost-effectiveness table comparing the three scenarios at which Direct Acting Antivirals are introduced in Thailand in the model.

| Scenario                  | Total Costs, USD (millions) | QALY *1000 | Incremental Costs USD (millions) | Incremental QALY | Incremental Cost Effectiveness Ratio | Cost effectiveness  |
|---------------------------|-----------------------------|-------------|---------------------------------|-----------------|--------------------------------------|----------------------|
| Immediate case, stage F0  | 29                          | 906         | –17                             | 6000            | 2833                                 | Most cost saving     |
| Early case, stage F1      | 41                          | 903         | –5                              | 3000            | 5755                                 | Dominated            |
| Base case, stage F2 stage | 46                          | 900         | NA                              | NA              | NA                                   | Dominated            |

### Discussion

Our model predicts that introducing DAAs immediately after HCV diagnosis among HIV-infected MSM is cost saving, i.e., reduced costs with gain in QALYs, which kicks in within a short timespan of 7 years of investment. For the first seven years, the undiscounted costs of immediate DAA treatment are higher than the current practice of delaying treatment to METAVIR stage F2 of liver fibrosis. After seven years, cost savings begin and can lead to a 42% reduced incidence rate, 80% reduced prevalence, and 12 times more infections averted through 2030 with immediate treatment. These results can encourage policy makers to invest in reimbursing immediate DAA treatment to promote reduced HCV burden within HIV-positive MSM.

Micro-elimination efforts have been frequently discussed as a strategy of HCV elimination among key populations that predominantly transmit the virus.11 HIV/HCV co-infected MSM would be an ideal target group for these efforts as this is a well-defined risk group that actively contributes to new HCV infections in Bangkok. If these men are regularly screened for HCV during HIV routine clinical care, they can be diagnosed early and can start immediate treatment to prevent onward transmission. Although our study has shown that immediate DAA treatment can reduce the HCV incidence among HIV-infected MSM, micro-elimination is not achieved in 2030. Therefore, additional measures, including needle exchange programs, more frequent HCV
screening and risk reduction programs must be considered to achieve the ambitious goal of ending HCV transmission by 2030.

Increasing testing to screen PrEP users for HCV infection could be a useful strategy for an early diagnosis of HCV-infected individuals, who may otherwise remain undiagnosed. PrEP is recommended to be used by MSM at high risk of HIV infection. However, PrEP medication sharing amongst MSM at risk has been reported. Consequently, MSM may start PrEP in informal settings without regularly being screened for HCV infection. Such informal use may facilitate HCV transmission as new infections are not diagnosed timely and subsequently remain uncured. Although the limited available information suggests that HCV is not frequently found amongst PrEP users, a surge cannot be ruled out. Therefore, micro-elimination of HCV transmission amongst MSM may in the future be targeted to all MSM at high risk of infection.

A direct policy implication of our study is that the cost of genotyping did not have any impact on the overall cost-effectiveness of immediate DAA treatment as per our sensitivity analysis. This is relevant since in the latest Thailand Practice Guideline for Eliminate Hepatitis C, 2020, genotyping is not required for pan-genotypic DAs. In November 2020, sofosbuvir/velpatasvir (pan genotypic DAs) became available in the National Health Security Office system and so genotyping is not required and will not be reimbursed. Since the impact of genotyping on cost-effectiveness is negligible, the revised policy guidelines are supported by our study results.

Several modelling studies from Asia share similar results showing that DAs are cost-effective over a lifetime from a payer’s perspective, with a few exceptions. The studies report costs, QALYs, ICER, as per the standard protocol that is followed in reporting cost-effectiveness modelling studies. The differences noted compared to our study are that firstly, other studies have used a Markov model, which contrary to our approach, does not account for the prevention of onward HCV transmission by DAs, thereby underestimating the epidemiological impact. Secondly, these studies do not target the HIV positive MSM population, and consequently do not have any implication on micro-elimination strategies. Thirdly, the cost-effectiveness studies conducted in other Asian countries are from Hong Kong, Japan, and Singapore, which are high-income countries and therefore not comparable to Thailand. Among other comparable low- and middle-income resource settings, China did not find it cost-effective to use DAs; a study conducted in Vietnam found DAs cost-effective but took interferon-based treatments as a comparison, while another study in India uses no DAs as a comparison scenario while concluding that they are cost-effective. Our study compares intervention scenarios of treatment using the same drug combination, sofosbuvir/ledipasvir, that DAAs are cost-effective over a lifetime from a payer’s perspective. MSM who are uninfected with HCV would be in the Thai context to get empirical estimates of reinfection among those cured of HCV after having been treated with DAs. Second, the modelling has not been conducted from a societal perspective but from a payer’s perspective. MSM who are uninfected with HCV would be healthier and reported ill less often when compared to HCV-infected MSM. There is evidence showing a loss in productivity from in the SEARCH study cohort have shown that Thai PWID and HIV positive MSM are two key populations where the HCV disease burden is concentrated.

In conclusion, reducing the HCV disease burden among HIV positive MSM in Bangkok is most cost-saving when DAs are introduced early as treatment and prevention strategy to reduce onward transmission. The Thai government investment in expanding DAs to immediately after diagnosis, would contribute to the WHO’s ambitious HCV elimination goals, but additional steps are required to eliminate HCV. An important consideration for governments is to examine the effects of any health investment in relation to their costs. Even if complete elimination is not possible, the incidence of HCV transmission at population level would be a priority for governments to be able to align with the WHO HCV elimination targets of 2030. To that extent, our study provides cost-effectiveness evidence on managing the disease amongst HIV positive MSM, a high-risk key population group, by immediately introducing DAA treatment. In its absence, rates of incidence and prevalence would keep increasing by 2030 leading to a huge cost burden to the Thai government.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jve.2021.100042.

References

1. Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–176. https://doi.org/10.1016/s2468-1253(16)30181-9.
2. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–1898. https://doi.org/10.1056/NEJMoa1402554.
3. Boerekamps A, van den Berk GE, Lauw FN, et al. Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus-positive men who have sex with men after unrestricted access to HCV therapy. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2018;66(9):1360–1365. https://doi.org/10.1093/cid/cix1007.
S. Mukherjee et al.

Journal of Virus Eradication 7 (2021) 100042

[4] Smit C, Boyd A, Rijnders BJA, et al. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study. Lancet HIV. 2020. https://doi.org/10.1016/s2352-3018(20)30310-5, Q(0).

[5] Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. CC BY-NC-SA 3.0 IGO.

[6] Wasson T, Pinyakorn S, Kolstieg CJ. Group sex and methamphetamine use fuel an explosive epidemic of hepatitis C among HIV-infected men who have sex with men in Bangkok. J Acquir Immune Defic Syndr. 2020;84(4):331–335.

[7] Thailand Practice Guideline for Eliminate Hepatitis C. 2020.

[8] Popping S, Hullegie SJ, Boerekamps A, et al. Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. PLoS One. 2019;14(1). https://doi.org/10.1371/journal.pone.0210179, e0210179-e0210179.

[9] van Griensven F, Kern CC, Ommue B, et al. Scaling up HIV treatment for MSM in Bangkok: What does it take? – a modelling and costing study. The World Bank: 2015:1–62.

[10] 2017 Thailand Progress Report Prevention and Control of AIDS. 2017. Thailand.

[11] Colby DJ, Nonenoy S, Waewklaihong S, et al. The perfect ice storm: mixing meth and hepatitis C in Thai MSM. CROI. 2020.

[12] Huang MH, Chang SY, Hung CC, et al. Viral Hepatitis HCV Reinfections after Viral Clearance Among HIV-Positive Patients with Recent HCV Infection in Taiwan. 2019:1860–1867. https://doi.org/10.1111/jin.14199, December 2018.

[13] Smith DJ, Jordan AE, Frank M, Hagan H. Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis. BMC Infect Dis. 2016;16(1). https://doi.org/10.1186/s12879-016-1807-3, 471–471.

[14] Thailand Practice Guideline for Management of Chronic Hepatitis C 2018. Vol. vol.12018.

[15] Lazarus JV, Wiktor S, Colombo M, Thurse M. Micro-elimination – A Path to Global Elimination of Hepatitis C. vol. 67. Elsevier B.V.; 2017:665–666. https://doi.org/10.1016/j.jhep.2017.06.033.

[16] Mansergh G, Mayer K, Hirshfield S, Stephenson R, Sullivan P. HIV pre-exposure prophylaxis medication sharing among HIV-negative men who have sex with men. JAMA Network Open. 2020;3(9). https://doi.org/10.1001/jamanetworkopen.2020.16256, e2016256-e2016256.

[17] Lo AOS, Chan HLY, Wong VWS, Wong GLH. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. J Gastroenterol Hepatol. 2017;32(5):1071–1078. https://doi.org/10.1111/jgh.13638.

[18] Yuen MF, Liu SH, Seto WK, et al. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. Digestive Diseases and Sciences; 2020. https://doi.org/10.1007/s10620-020-03281-8.

[19] Kawaguchi I, Chayama K, Gonzalez YS, et al. A cost-effectiveness analysis of glecaprevir/pibrentasvir versus existing direct-acting antivirals to treat chronic hepatitis C in Japan. Adv Ther. 2020;37(1):457–476. https://doi.org/10.1007/s12325-019-01166-5.

[20] Wong VJ, Cheen MIIH, Hsiang JYC, et al. Economic evaluation of direct-acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore. JGH Open. 2019;3(3):210–216. https://doi.org/10.1097/jghb.3.12139.

[21] Chen G-S, Wei L, Chen J, Duan Z-p, Dou X-g. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. 2016:1–13. https://doi.org/10.1371/journal.pone.0155934.

[22] Due OT, Thakkinstian A, Thavorncharoensap M, et al. Cost-utility analysis of direct-acting antivirals for treatment of chronic hepatitis C genotype 1 and 6 in Vietnam. Value Health. 2020;23(9):1180–1190. https://doi.org/10.1016/j.jval.2020.03.018.

[23] Chaillon A, Mehta SR, Hoenigl M, et al. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS One. 2019;14(6). https://doi.org/10.1371/journal.pone.0217664.

[24] Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology. 2010;52(2):436–442. https://doi.org/10.1002/hep.23726.

[25] Han WM, Colby DJ, Khlaiphiuengin A, et al. Large transmission cluster of acute hepatitis C identified among HIV-positive men who have sex with men in Bangkok, Thailand. Liver Int. 2020;40(9):2104–2109. https://doi.org/10.1111/liv.14578.

[26] World Population Prospects 2019. United Nations; 2019.

[27] May MT, Gompels M, Delphe V, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014;28(8):1193–1202. https://doi.org/10.1097/QAD.0000000000000243.

[28] Micalef JM, Kaldor JM, Dorf GI. Spontaneous Viral Clearance Following Acute Hepatitis C Infection: A Systematic Review of Longitudinal Studies. vol. 13. John Wiley & Sons, Ltd; 2006:34–41. https://doi.org/10.1111/j.1365-2893.2005.00651.x.

[29] Thomson EC, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1 infected men. Gut. 2011;60(6):837–845. https://doi.org/10.1136/gut.2010.217166.

[30] Ghany MG, Morgan TR. Hepatitis C Guidance 2019 update: American association for the study of liver diseases–infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721. https://doi.org/10.1002/hep.31060.

[31] Pawlotsky JM, Negro F, Aghezzo A, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018. https://doi.org/10.1016/j.jhep.2018.03.026.

[32] Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002;22(6):475–481. https://doi.org/10.1177/0272989x02238300.

[33] Li P, Bd M, Ij A, et al. The cost-effectiveness of improved HCV therapies in HIV/HCV co-infected individuals. AIDS (London, England). 2014;28(3). https://doi.org/10.1097/QAD.0000000000000265.

[34] Siriraprasiri T, Khemngern P, Ruchharopornpanich O, Monyarit S. Thailand AIDS Response Progress Report. 2017.